Landing Medical Opens AI-Powered Cervical Cancer Screening Cloud Platform Along the Belt and Road, Files IPO Prospectus

Now in its sixth year, the Belt and Road Initiative (BRI) has enabled China to share more than just infrastructure such as transportation and energy with participating countries; advanced domestic medical technologies are also gradually transforming the daily lives of people along the routes.

Take Indonesia as an example. This archipelagic nation, comprising 17,000 islands, faces significant transportation challenges in healthcare delivery. Patients often need to travel from one island to another to seek medical care, multiplying their healthcare costs several fold.

To address this issue, Wuhan Landing Medical High-Tech Co., Ltd. (hereinafter referred to as "Landing Medical"), based in Wuhan, is integrating technologies such as the Internet of Things (IoT), the internet, cloud platforms, and artificial intelligence (AI) to improve cervical cancer screening for residents in Indonesia. Supported by Landing’s “AI + Cloud Diagnosis” technology, women no longer need to make multiple hospital visits for sample collection, report pickup, and result analysis. After cellular specimen images are collected, the relevant data is uploaded via the internet to the Landing Cloud Platform for intelligent diagnosis, allowing screened women to access their reports on their mobile phones at home. This technology has brought significant convenience to cervical cancer screening for Indonesian women and accelerated the widespread adoption of such screening in the country.

This technology is expanding from China to more countries along the Belt and Road Initiative. On March 28, 2019, the Chinese Association of Maternal and Child Health Studies and the Landing AI Cytology Diagnostic Center at Wuhan University announced in Beijing that the Landing AI Cloud Diagnostic Platform for Cervical Cancer Screening would be opened to the world starting April 1. Women worldwide, particularly those in countries along the Belt and Road Initiative, are expected to benefit from high-quality, low-cost cervical cancer screening services provided by this Chinese AI cloud diagnostic platform.

Traditional cytological screening for cervical cancer relies on medical technicians performing diagnoses under a microscope based on their experience. According to international standards, the daily slide review volume for each technician should be less than 100 cases. As humans are not machines, it is impossible to entirely eliminate diagnostic errors caused by fatigue or variations in experience. However, the AI-powered cervical cancer diagnostic robot “Landing,” developed by Landing Medical, assists physicians in accurately detecting early precancerous lesions of the cervix, making cervical cancer highly likely to become the first malignant tumor eradicated through preventive screening.

Leveraging this AI technology, Landing Medical has established over 400 “Landing Standard Cytology Laboratories” across China, with coverage extending to tertiary hospitals in provincial capitals, secondary hospitals in small and medium-sized cities, and even grassroots family planning stations in rural areas.

According to reports, the Landing AI Cytopathology Diagnosis Research Center at Wuhan University is a research institution characterized by multidisciplinary expertise and the integration of industry, academia, and research. It primarily focuses on the research and development, production, and clinical application of AI-based cytopathological diagnosis. After 17 years of arduous efforts and the accumulation of data from millions of clinical samples, the center has established a comprehensive, unified hardware and software system for AI-driven cytopathological diagnosis.

This technology has been deployed on a large scale for many years across various provinces and cities, including Hubei, Shanxi, Yunnan, Henan, and Shenzhen, providing cervical cancer screening services to millions of urban and rural women annually. It has accumulated a substantial volume of valuable clinical data and obtained product approvals in overseas markets, including the United States and the European Union.

This novel screening model marks the end of an era in which cervical cancer screening relied on expert experience for diagnosis. By leveraging big data to enhance diagnostic quality and modern technology to reduce costs, it improves the efficiency of large-scale cervical cancer screening as well as the detection rates of precancerous lesions and positive cases, playing a significant role in reducing the incidence and mortality of cervical cancer. Furthermore, it provides a practical solution to the common challenge faced by developing countries worldwide: the shortage of specialized personnel for tumor screening at the primary healthcare level. To date, Wuhan Landing Medical High-Tech Co., Ltd. has completed more than 2 million cervical cancer screenings.

Building on AI-assisted diagnosis, Landing Medical has launched an AI-powered cloud platform for cervical cancer screening. This platform connects previously isolated testing sites, consolidates data, and breaks down information barriers, thereby providing patients with faster and more accurate cervical cancer screening services.

After years of accumulation, Landing Cloud has been developed into a comprehensive cervical cancer diagnosis platform integrating diagnosis, management, data analysis, teaching, and scientific research. It serves as a crucial foundation for innovative R&D, technology implementation, and industrial development of artificial intelligence in the field of medical diagnosis. Specifically, the features and functions of “Landing Cloud” can be summarized in the following five points:

First, “Landing Cloud” is an AI-powered diagnostic platform. After years of accumulation and R&D, Landing has developed the CytoBrain AI engine for cervical cancer cell recognition, which features independent intellectual property rights and is deployed on the cloud.

The CytoBrain AI engine can replace cytology screeners. For countries along the “Belt and Road” that seek to reduce the labor costs of manual slide review in cervical cancer screening or lack specialized screening personnel, “Landing Cloud” provides low-cost, high-quality AI-based cytology screening services, thereby reducing the incidence and mortality rates of cervical cancer in these regions.

Second, “Landing Cloud” is a platform for organizational management. Cervical cancer screening is a systematic endeavor in every country and region worldwide. The smooth implementation of such programs imposes higher demands on organizational management, process management, personnel training and assessment, monitoring of screening quality, and data analysis and statistics.

“Landing Cloud” summarizes the experience gained from undertaking and participating in large-scale cervical cancer screening projects at the primary care level across China. The platform, built on artificial intelligence, internet, and cloud computing technologies, offers robust elasticity and customizability. It has been thoroughly validated and tested in multiple cervical cancer screening projects throughout China, becoming increasingly mature. With this open launch, Wuhan Landing Medical High-Tech Co., Ltd. can accommodate diverse management needs from organizations and administrative bodies overseeing cervical cancer screening projects worldwide. By providing open services globally, the company aims to promote its proven expertise and technology in cervical cancer screening project management to the world.

Third, “Landing Cloud” is also a big data analytics platform. “Landing Cloud” is currently the world’s largest cytopathology database for cervical cancer. After decades of development and application, it has accumulated millions of cervical cancer cytology cases. These data are of significant importance for research on the diagnosis and treatment of cervical cancer, the pathogenesis of cancer, regional epidemiology, and trends in incidence and mortality rates.

In the Outline for Promoting the Development of Big Data, the State Council proposed that big data has become a new driving force for economic transformation and development, a new opportunity to reshape national competitive advantages, and a new approach to enhancing government governance capabilities. Wuhan Landing Medical High-Tech Co., Ltd. is willing to gradually open these data to relevant global research institutions and government organizations on the basis of ensuring data security, so as to promote data-driven scientific decision-making in cervical cancer prevention worldwide.

Fourth, “Landing Cloud” also serves as an educational platform. For countries along the Belt and Road Initiative, particularly developing nations, training cytotechnologists and physicians is a key focus and challenge in cervical cancer screening. Due to characteristics such as limited preservation time for cytopathology specimens, high subjectivity in diagnosis, and poor reproducibility, there has been no unified or effective standard for training and education.

“Landing Cloud” leverages decades of cervical cancer screening projects across multiple provinces and regions, having collected extensive case data that has been fully digitized for storage and diagnosis. Additionally, by harnessing AI technology, we have developed the Smart CytoSchool platform for cytodiagnostic education. This platform provides innovative approaches and pathways for training cytopathologists in China. We will gradually open access to these data resources and the AI-powered educational platform to cytopathologists in countries along the “Belt and Road” initiative, contributing to the improvement of global cervical cancer diagnostic standards.

Fifth, “Landing Cloud” serves as a robust platform for scientific research. As previously mentioned, “Landing Cloud” has accumulated substantial data through its involvement in China’s cervical cancer screening programs, and it will continue to gather even more data as it expands to provide global cervical cancer diagnostic services. The data amassed by “Landing Cloud” encompasses not only cytopathological images but also high-quality diagnostic marker data, regional demographic statistics, epidemiological analysis data, and other multi-dimensional, multi-source datasets.

These data serve as excellent resources for research in cytopathology, epidemiology, artificial intelligence, and big data. Wuhan Landing Medical High-Tech Co., Ltd. will make the data available to researchers and institutions worldwide after de-identification, while ensuring data security.

In the future, Landing Medical will gradually open up its Landing Cloud Platform—an integrated system for diagnosis, management, data analysis, teaching, and scientific research—to promote Chinese technology, Chinese data, and Chinese standards worldwide. We are committed to sharing data, conducting joint research, sharing outcomes, and co-creating the future.

Today, Landing Medical’s AI products have obtained NMPA, FDA, and CE certifications. These multiple approvals will help Landing establish a benchmark standard for cervical cancer screening worldwide.

Regarding the robust growth of Landing Medical, Zhao Baige, Chairman of the Expert Committee of the Belt and Road International Think Tank at the Chinese Academy of Social Sciences, stated: “Landing’s success is evident to all. On one hand, Landing has integrated technologies from the Fourth Industrial Revolution, including the Internet of Things (IoT), the internet, artificial intelligence (AI), and cloud computing. On the other hand, it has effectively bridged governmental and non-governmental forces, aligning with the development of the Belt and Road Initiative to successfully introduce China’s cervical cancer screening technology to overseas markets. Currently, Landing holds multiple medical device approval certificates. With state support, it is entirely possible for the company to elevate its enterprise standards to national industry standards.”

While advancing the development of the Belt and Road Initiative, Landing Medical will continue to focus on domestic growth in China. It is projected that by 2020, Landing Medical will establish 100 county-level laboratories, each benefiting 1,000 individuals, and 10 provincial-level laboratories, each serving 10,000 patients, thereby enabling more women to benefit from technological advancements.